Peri - and Intraocular Mutilating Advanced Squamous Cell Carcinoma: ʺMonsters Inside Your Bodyʺ?

Authors

  • Georgi Tchernev Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia; ”Onkoderma”- Policlinic for Dermatology and Dermatologic Surgery, Sofia
  • Torello Lotti University G. Marconi of Rome - Dermatology and Venereology, Rome
  • Ilia Lozev Medical Institute of Ministry of Interior Department of General, Vascular and Abdominal Surgery, Sofia
  • Georgi Konstantinov Maximov ”Onkoderma”- Policlinic for Dermatology and Dermatologic Surgery, Sofia
  • Uwe Wollina Städtisches Klinikum Dresden - Department of Dermatology and Allergology, Dresden, Sachsen

DOI:

https://doi.org/10.3889/oamjms.2018.013

Keywords:

Periocular malignancies, Surgery, Mohs, Cetuximab, Endoxan

Abstract

Periocular malignancies represent between 5% and 10% of all types of skin cancers. The incidence of eyelid (but also the periocular located) malignancies seems to differ in distribution across the continents.  The incidence of eyelid tumours (but also the periocular located tumours) in a predominantly white population determined that BCC is the most common malignant periocular eyelid tumour in whites. This finding has been replicated consistently throughout the literature, with BCC representing 85–95% of all eyelid malignancies, SCC representing 3.4 - 12.6%, Seb Ca representing 0.6 - 10.2%, and both melanoma and Merkel cell carcinoma representing less than 1%. Most periocular skin cancers are associated with ultraviolet radiation (UVR) exposure. Ultraviolet radiation causes local immune suppression, which, coupled with DNA abnormalities in tumour suppressor genes and oncogenes, leads to the development of skin cancers.  We are presenting a 62 - year - old patient with a small nodule about 2 cm away from the lower lid of his left eye. A tumour was surgically treated. Several years later there was a tumour relapse, treated with radiotherapy and subsequent chemotherapy with Endoxan and Cisplatin. After the second relapse, he was treated surgically in general anaesthesia by orbital exenteration, removal of the orbital floor and resection of zygomatic bone and the maxillary sinus. A couple of months later, he developed a tumour relapse in the scars and the area of a primary tumour with tumour progression. A possible therapy with Cetuximab or radiation therapy was discussed as a possible treatment option.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Sun MT, Andrew NH, O'Donnell B, McNab A, Huilgol SC, Selva D. Periocular squamous cell carcinoma: TNM staging and recurrence. Ophthalmology. 2015; 122(7):1512-6. https://doi.org/10.1016/j.ophtha.2015.04.002 PMid:25972255

Karabekmez FE, Selimoglu MN, Duymaz A, Karamese MS, Keskin M, Savaci N. Management of neglected periorbital squamous cell carcinoma requiring orbital exenteration. J Craniofac Surg. 2014; 25(3):729-34. https://doi.org/10.1097/SCS.0000000000000333 PMid:24481161

Nassab RS, Thomas SS, Murray D. Orbital exenteration for advanced periorbital skin cancers: 20 years experience. J Plast Reconstr Aesthet Surg. 2007; 60(10):1103-9. https://doi.org/10.1016/j.bjps.2007.02.012 PMid:17434350

Wollina U. Update of cetuximab for non-melanoma skin cancer. Expert Opin Biol Ther. 2014; 14(2):271-276. https://doi.org/10.1517/14712598.2013.876406 PMid:24387664

Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014; 25(5):424-427. https://doi.org/10.3109/09546634.2012.751481 PMid:23167307

Heath CH, Deep NL, Nabell L, Carroll WR, Desmond R, Clemons L, Spencer S, Magnuson JS, Rosenthal EL. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013; 85(5):1275-1281. https://doi.org/10.1016/j.ijrobp.2012.09.030 PMid:23182701 PMCid:PMC3607201

Sullivan TJ. Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens. Curr Opin Ophthalmol. 2012; 23: 439–442. https://doi.org/10.1097/ICU.0b013e328356ad55 PMid:22828167

Silverman N, Shinder R. What's New in Eyelid Tumors. Asia Pac J Ophthalmol (Phila). 2017; 6(2):143-152. https://doi.org/10.22608/APO.201701 PMid:28399340

Published

2018-01-13

How to Cite

1.
Tchernev G, Lotti T, Lozev I, Maximov GK, Wollina U. Peri - and Intraocular Mutilating Advanced Squamous Cell Carcinoma: ʺMonsters Inside Your Bodyʺ?. Open Access Maced J Med Sci [Internet]. 2018 Jan. 13 [cited 2021 Apr. 11];6(1):132-3. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.013

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>